logo-loader

Akers Bio’s chief: HIT test market a billion dollar opportunity

Published: 11:13 01 Oct 2015 EDT

Raymond Akers, chief executive of Akers Biosciences (LON:AKR), reckons the global heparin-induced thrombocytopenia (HIT) test industry is not far away from being valued as a US$1bn market.

Akers is a front runner in the space and has distribution for its own HIT test in every major diagnostic market after inking agreements for India, Germany, Italy and Scandinavia.

Millions of patients are exposed to heparin around the world each year and between 1% and 5% of those patients receive a HIT diagnosis.

The test is the only US and EU cleared rapid test to detect a potentially fatal allergy to the widely used blood thinner, heparin.

That allergy reverses the effect of heparin and turns it into a clotting agent, which is clearly very dangerous.

M2i Global merges with Volato Group, gaining NYSE American Listing and...

M2i Global CEO Alberto Rosende joined Steve Darling from Proactive to announce a transformative step for the company: the signing of a non-binding term sheet to be acquired by the Volato Group, a U.S.-based, technology-first aviation firm known for its innovations in aviation software and...

1 day, 1 hour ago
OSZAR »